Literature DB >> 18396243

Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice.

Ahmed H Abdelhafiz1, Nigel M Wheeldon.   

Abstract

BACKGROUND: The prevalence of atrial fibrillation increases with age, affecting approximately 5% of people aged >65 years and almost 10% of people aged >80 years.
OBJECTIVE: The goal of this study was to identify risk factors for bleeding during warfarin treatment of nonvalvular atrial fibrillation (NNVAF) in older patients (those aged >or=75 years) compared with younger patients (those aged <75 years) in clinical practice.
METHODS: All patients with NVAF newly started on warfarin at an anticoagulation clinic in a large university hospital were included in this prospective observational study. Patient details were recorded at their first visit; details of any bleeding events were recorded via telephone interview every 4 to 6 weeks for a minimum of 10 months. Patients were divided into 2 groups (ie, those >or=75 years old and those <75 years old). Logistic regression analysis was used to identify risk factors for bleeding.
RESULTS: A total of 402 patients were included in the study. Group I comprised 203 patients <75 years old (mean [SD] age, 64.33 [8.33] years) and group II comprised 199 patients >or=75 years old (mean [SD] age, 80.44 [3.99] years). Follow-up ranged from 1 to 31 months (mean [SD], 19 [8.11] months). For major bleeding, number of medications was a significant risk factor in older patients (odds ratio [OR], 3.0; 95% CI, 1.2-7.8 [P = 0.02 ]) and range of the international normalized ratio (INR) was a significant risk factor in both groups. For every unit increase in the range of INR, the odds of major bleeding increased by 0.6 (OR, 1.6; 95% CI, 1.2-2.4 [P = 0.03 ]) in younger patients and by 0.4 (OR, 1.4; 95% CI, 1.07-1.99 [P = 0.04 ])in older patients. For minor bleeding, history of hypertension was the only significant risk factor in older patients (OR, 3.3; 95% CI, 1.3-8.1 [P = 0.01 ]), while history of ischemic heart disease was the only risk factor in younger patients (OR, 1.9; 95% CI, 1.1-5.4 [P = 0.04 ]).
CONCLUSIONS: Bleeding pattern was similar in both age groups regarding severity, onset, anatomic site of bleeding, and INR values during the bleeding event. Risk factors for episodes of major bleeding, which are more of a clinical concern, are potentially modifiable. They include quality of anticoagulation control in both groups and number of medications in the older age group.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18396243     DOI: 10.1016/j.amjopharm.2008.03.005

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  15 in total

Review 1.  Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.

Authors:  Julie Kalabalik; Gail B Rattinger; Jesse Sullivan; Malgorzata Slugocki; Antonia Carbone; Anastasia Rivkin
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

2.  Prescribing warfarin appropriately to meet patient safety goals.

Authors:  Lekshmi Dharmarajan; T S Dharmarajan
Journal:  Am Health Drug Benefits       Date:  2008-07

3.  Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism.

Authors:  Waltraud Leiss; Marie Méan; Andreas Limacher; Marc Righini; Kurt Jaeger; Hans-Jürg Beer; Joseph Osterwalder; Beat Frauchiger; Christian M Matter; Nils Kucher; Anne Angelillo-Scherrer; Jacques Cornuz; Martin Banyai; Bernhard Lämmle; Marc Husmann; Michael Egloff; Markus Aschwanden; Nicolas Rodondi; Drahomir Aujesky
Journal:  J Gen Intern Med       Date:  2014-08-21       Impact factor: 5.128

Review 4.  New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.

Authors:  Birgitte Klindt Poulsen; Erik Lerkevang Grove; Steen Elkjaer Husted
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

Review 5.  Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.

Authors:  Wendy T Chen; C Michael White; Olivia J Phung; Jeffrey Kluger; Ajibade O Ashaye; Diana M Sobieraj; Sagar Makanji; Vanita Tongbram; William L Baker; Craig I Coleman
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

6.  Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study.

Authors:  Raymond C S Seet; Alejandro A Rabinstein; Teresa J H Christianson; George W Petty; Robert D Brown
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-03-15       Impact factor: 2.136

7.  Enzyme-amplified array sensing of proteins in solution and in biofluids.

Authors:  Oscar R Miranda; Hung-Ting Chen; Chang-Cheng You; David E Mortenson; Xiao-Chao Yang; Uwe H F Bunz; Vincent M Rotello
Journal:  J Am Chem Soc       Date:  2010-04-14       Impact factor: 15.419

Review 8.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

9.  Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.

Authors:  Elizabeth S Mearns; C Michael White; Christine G Kohn; Jessica Hawthorne; Ju-Sung Song; Joy Meng; Jeff R Schein; Monika K Raut; Craig I Coleman
Journal:  Thromb J       Date:  2014-06-24

Review 10.  Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE).

Authors:  Xin Zhang; Qiyan Cai; Xiaohui Wang; Ke Liao; Changchun Hu; Hong Chen
Journal:  J Thromb Thrombolysis       Date:  2021-03-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.